TBPH - Earnings announcements

YUPELRI® Collaboration Revenue increased 15% year-over-year1, from $15.4 million to $17.7 million, driven by continued Net Sales growth and improved operating leverageAll Hatch-Waxman litigation relating to YUPELRI® has been resolved following settlement with Mankind Pharma in MarchOrganizational restructuring and cost reduction initiatives on track; delivered ~20% reduction in Operating Expenses year-over-year (excluding restructuring items)Q1 2026 TRELEGY net sales, reported by GSK, of $873 million, up 2% year-over-year; high confidence in achieving the $100 million 2026 milestone payment2Strategic Review Committee actively evaluating a range of opportunities to maximize shareholder valueQ

Organizational restructuring and cost reduction plan following results of the Phase 3 CYPRESS study of ampreloxetine are underway; expected to generate $60 - $70 million of annualized cash flow starting in Q3 2026Strategic Review Committee accelerating evaluation of opportunities to maximize shareholder valueYUPELRI® achieved record brand profitability for Q4 and full-year 2025; full-year net sales of $266.6 million, recognized by Viatris, up 12% year-over-year1 resulting in a $25 million milestone payment Full-year 2025 TRELEGY net sales, reported by GSK, of $3.9 billion, up 12% year-over-year, triggered a $50 million milestone payment; high confidence in achieving the $100 million 2026 mil

DUBLIN, Nov. 20, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ:TBPH) today announced that it will host a virtual key opinion leader (KOL) investor event on Monday, December 8, 2025 at 10:30 AM ET. To register, click here. The event will feature Horacio Kaufmann, MD (Dysautonomia Center, NYU Langone Health), who will join company management to discuss the unmet medical need for symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA), a chronic, debilitating condition caused by autonomic dysfunction that is present in ~80% of

YUPELRI® net sales reached an all-time high of $71.4 million, recognized by Viatris, up 15% year-over-year1, and achieved record brand profitabilityOpen-label portion of the pivotal Phase 3 CYPRESS study of ampreloxetine now complete; topline readout on track for Q1 2026Company to host an ampreloxetine focused virtual Key Opinion Leader (KOL) event for investors on December 8, 2025TRELEGY year-to-date sales on track to achieve $50 million milestone in 20252Strong balance sheet with $333 million in cash and no debtDUBLIN, Nov. 10, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ:TBPH) today reported financial and operational results for the thi

Ampreloxetine clinical development program to be featured in four presentations at the upcoming International Symposium on The Autonomic Nervous SystemTopline results from the ongoing Phase 3 CYPRESS study of ampreloxetine anticipated in Q1 2026DUBLIN, Oct. 29, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ:TBPH) today announced that it will be participating at the 36th International Symposium on the Autonomic Nervous System, organized by the American Autonomic Society (AAS), taking place November 5-8, 2025, in Clearwater Beach, FL. The Company will have one platform presentation and three poster presentations on its clinical development program for ampreloxetine, a potential first-

DUBLIN, Oct. 27, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ:TBPH) will report its third quarter 2025 financial results and provide a business update after market close on Monday, November 10, 2025. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm EST (2:00 pm PST / 10:00 pm GMT) that day. Conference Call Information To participate in the live call by telephone, please pre-register here. Those interested in the live audio webcast of the conference call may access it by clicking here or visiting the Events and Presentation page unde

Topline results anticipated in Q1 2026 and, if successful, planning for expedited NDA submission If approved, ampreloxetine could address a critical unmet need as the first therapy with the potential to provide durable benefit for the 40,000 patients in the U.S. with symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA)Ampreloxetine has Orphan Drug Designation in the U.S., underscoring the unmet need in symptomatic nOH due to MSADUBLIN, Aug. 25, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ:TBPH), today announced completion of enrollment in the open-label portion of its pivotal Phase 3 CYPRESS s

YUPELRI® (revefenacin) net sales of $66.3 million, recognized by Viatris, increased 22% year-over-year1Pivotal Phase 3 CYPRESS study enrollment on track to complete by late summerCompleted sale of TRELEGY ELLIPTA royalty interest to GSK for $225 millionTRELEGY year-to-date sales on track to trigger $50 million milestone in 2025Strong balance sheet with $339 million in cash and no debtDUBLIN, Aug. 12, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ:TBPH) today reported financial and operational results for the second quarter of 2025.

DUBLIN, July 28, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ:TBPH) will report its second quarter 2025 financial results and provide a business update after market close on Tuesday, August 12, 2025. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm ET (2:00 pm PT / 9:00 pm GMT) that day. Conference Call Information To participate in the live call by telephone, please pre-register here. Those interested in listening to the conference call live via the internet may do so by clicking here or visiting the Events and Presentation page un

YUPELRI® (revefenacin) net sales of $58.3 million, recognized by Viatris, increased 6% versus Q1 20241 TRELEGY net sales of $854M, as reported by GSK, increased 14% versus Q1 20242CYPRESS study open label enrollment nearing completion with final patient expected to be enrolled by late summerQuarter-end cash balance of $131 million, with no debtReaffirming all financial guidance metricsDUBLIN, May 8, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ:TBPH) today reported financial and operational results for the first quarter of 2025.

DUBLIN , April 24, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ:TBPH) will report its first quarter 2025 financial results and provide a business update after market close on Thursday, May 8, 2025. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm EDT (2:00 pm PDT/10:00 pm IST) that day. Conference Call Information To participate in the live call by telephone, please dial (800) 715-9871 from the US or (646) 307-1963 for international callers, using the Conference ID 3369474. Those interested in listening to the conference call live v

YUPELRI® (revefenacin) US net sales, recognized by Viatris, reached an all-time high of $66.7 million in Q4 2024 and $238.6 million in FY 2024, up 10% and 8%, respectively, compared with 20231FY 2024 TRELEGY Net Sales, as reported by GSK, of $3.46 billion, up 26% compared with 2023 and triggering a $50 million milestone to Theravance Biopharma2,3CYPRESS study on track to enroll final patient in the open label portion by mid-2025Ended Q4 2024 with $88 million in cash, excluding the $50 million TRELEGY milestone, with cash receipt in February 2025DUBLIN, Feb. 26, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ:TBPH) today announced financial an

DUBLIN, Ireland, Feb. 12, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ:TBPH) will report its fourth quarter and full year 2024 financial results and provide a business update after market close on Wednesday, February 26, 2025. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm EST (2:00 pm PST/10:00 pm GMT) that day. Conference Call Information To participate in the live call by telephone, please pre-register here. Those interested in listening to the conference call live via the internet may do so by visiting Theravance Biopharma's w

Third quarter results highlight strong operational performance across key value drivers:YUPELRI® (revefenacin) net sales of $62.2 million, recognized by Viatris, an all-time high, increased 7% versus Q3 2023 and 14% versus Q2 20241CYPRESS enrollment in-line with expectations, with timelines on trackTRELEGY net sales increased 17%, to $789 million, as reported by GSK:Q4 sales of at least ~$260 million needed to earn $25 million milestone2Q4 sales of at least ~$610 million needed to earn $50 million milestone2Board of Directors announces initiatives to unlock shareholder value and enhance corporate governanceDUBLIN, Nov. 12, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharm

DUBLIN, Oct. 24, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ:TBPH) will report its third quarter 2024 financial results and provide a business update after market close on Tuesday, November 12, 2024. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm EST (2:00 pm PST/10:00 pm GMT) that day. Conference Call Information To participate in the live call by telephone, please pre-register here. Those interested in listening to the conference call live via the internet may do so by visiting Theravance Biopharma's website at www.theravance.c

Q2 2024 YUPELRI® (revefenacin) net sales of $54.5 million, recognized by Viatris, decreased 1% from Q2 20231Viatris collaboration revenue of $14.3 million, increased 4% versus Q2 2023Partner Viatris submitted YUPELRI NDA in China; $7.5 million milestone if approvedNow expecting last patient into the open label portion of CYPRESS in mid-2025, top line data anticipated approximately 6 months laterQ2 2024 TRELEGY net sales of $1.065 billion, increasing the likelihood of achieving up to $50 million of milestones in 2024Q2 2024 ending cash balance of $96.1 millionDUBLIN, Aug. 5, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ:TBPH) today announced

DUBLIN, July 22, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ:TBPH) will report its second quarter 2024 financial results and provide a business update after market close on Monday, August 5, 2024. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm ET (2:00 pm PT/10:00 pm IST) that day. Conference Call Information To participate in the live call by telephone, please pre-register here. Those interested in listening to the conference call live via the internet may do so by visiting Theravance Biopharma's website at www.theravance.com, u

Q1 2024 YUPELRI® (revefenacin) net sales of $55.2 million, recognized by Viatris, increased 18% from Q1 20231Viatris collaboration revenue of $14.5 million, increased 39% versus Q1 2023, reflecting margin improvementContinued progress for ampreloxetine CYPRESS enrollmentVirtual ampreloxetine KOL event scheduled for May 23, 2024Q1 2024 ending cash balance of $100 millionDUBLIN, May 13, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ:TBPH) today announced financial and operational results for the first quarter of 2024. "Building

DUBLIN, April 29, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ:TBPH) will report its first quarter 2024 financial results and provide a business update after market close on Monday, May 13, 2024. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm ET (2:00 pm PT/10:00 pm IST) that day. Conference Call Information To participate in the live call by telephone, please pre-register here. Those interested in listening to the conference call live via the internet may do so by visiting Theravance Biopharma's website at www.theravance.com, und

Q4 2023 YUPELRI® (revefenacin) net sales, recognized by Viatris, increased 9% from Q4 2022, reaching an all-time high of $60.6 million1Full Year 2023 Viatris Collaboration Revenue increased 18% to $57.2 millionGAAP Net Loss of $8.5 million in Q4; Achieved goal of profitability on Non-GAAP basis in Q4, with Non-GAAP Net Profit of $1.4 million2Completed $325 million capital return program, reducing shares outstanding by 37% Ampreloxetine investor event planned for Q2 2024DUBLIN, Feb. 26, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ:TBPH) today announced financial and operational results for the fourth quarter of 2023 and full-year ended Dece

DUBLIN, Feb. 14, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ:TBPH) will report its fourth quarter and full year 2023 financial results and provide a business update after market close on Monday, February 26, 2024. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm ET (2:00 pm PT/10:00 pm GMT) that day. Conference Call Information To participate in the live call by telephone, please pre-register here. Those interested in listening to the conference call live via the internet may do so by visiting Theravance Biopharma's website at www.

Q2 2023 YUPELRI® (revefenacin) net sales of $55.0 million, recognized by Viatris, up 12% from Q2 20221Q2 2023 YUPELRI total retail TRx and new to product TRx again reached all-time highs, up 26% and 53%, Y/Y, respectively2PIFR-2 enrollment nearing completion; top-line data in late Q4 2023, with disclosure anticipated in January 2024Company expects to complete $325 million capital return program by year-end, having returned $80.5 million via share repurchases during Q2 2023 and $263.8 million since inception through quarter endDUBLIN, Aug. 7, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ:TBPH) today announced financial and operational result

DUBLIN, July 24, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ:TBPH) will report its second quarter 2023 financial results and provide a business update after market close on Monday, August 7, 2023. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm ET (2:00 pm PT/10:00 pm IST) that day. Conference Call Information To participate in the live call by telephone, please pre-register here. Those interested in listening to the conference call live via the internet may do so by visiting Theravance Biopharma's website at www.theravance.com, u

Q1 2023 YUPELRI® (revefenacin) net sales of $47.0 million, recognized by Viatris, up 8% from Q1 20221Q1 2023 YUPELRI retail new patient starts and total prescriptions up 61% and 29%, respectively, year-over-year, reaching all-time highs2CYPRESS Phase 3 study of ampreloxetine recruiting; anticipate completing enrollment during H2 2024On track to complete $325 million capital return program by year-end; completed $215 million of share repurchases from inception through 4/30/23Jim Kelly, Managing Director at Weiss Asset Management, joins Board of DirectorsDUBLIN, May 8, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ:TBPH) today announced financ

DUBLIN, April 24, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ:TBPH) will report its first quarter 2023 financial results and provide a business update after market close on Monday, May 8, 2023. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm ET (2:00 pm PT/10:00 pm IST) that day. Conference Call Information To participate in the live call by telephone, please pre-register here. Those interested in listening to the conference call live via the internet may do so by visiting Theravance Biopharma's website at www.theravance.com, unde

Increases capital return program to $325 million from $250 million; as of 2/27/23, approximately $170 million remains in the programDiscontinuing investments in research, reducing headcount by approximately 17%Reports highest quarter of YUPELRI® (revefenacin) net sales and profitability to date; $19.5 million Q4 2022 sales up 27% from Q4 2021 (TBPH implied 35% share)1On track to begin enrollment in ampreloxetine Phase 3 study in Q1 2023Appoints Susannah Gray to Board as new Independent DirectorCommits to declassify the Board of DirectorsDUBLIN, Feb. 27, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ:TBPH) today announced financial results fo

DUBLIN, Feb. 21, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ:TBPH) will report its fourth quarter and full year 2022 financial results and provide a business update after market close on Monday, February 27, 2023. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm ET (2:00 pm PT/10:00 pm GMT) that day. Conference Call Information To participate in the live call by telephone, please pre-register here. Those interested in listening to the conference call live via the internet may do so by visiting Theravance Biopharma's website at www.

Reported another record quarter of YUPELRI® (revefenacin) net sales and profitability: $18.7 million Q3 2022 sales up 35% from Q3 2021 (TBPH implied 35% share)1Presented ampreloxetine data in neurogenic orthostatic hypotension (nOH) at the 33rd International Symposium on the Autonomic Nervous SystemContinued to build the Company's intellectual property portfolio with patent covering YUPELRI until 2039Closed transaction to sell TRELEGY ELLIPTA royalty interests to Royalty Pharma for approximately $1.1 billion in upfront cash, up to $250 million of potential milestones, outer year royalties and an investment in ampreloxetine Initiated a $250 million capital return program; purchased GSK's enti

DUBLIN, Oct. 31, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ:TBPH) will report its third quarter 2022 financial results and provide a business update after market close on Monday, November 7, 2022. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm ET (2:00 pm PT/10:00 pm GMT) that day. Conference Call Information To participate in the live call by telephone, please pre-register here. Those interested in listening to the conference call live via the internet may do so by visiting Theravance Biopharma's website at www.theravance.com,

Highest quarter of YUPELRI® (revefenacin) net sales and profitability to date1: $17.2M Q2 2022 sales up 17% from Q2 2021 (implied 35% share) Ampreloxetine discussions with FDA create a path to NDA filing with one additional Phase 3 clinical study in Multiple System Atrophy (MSA) patients with symptomatic neurogenic orthostatic hypotension (nOH)Closed transaction to sell TRELEGY ELLIPTA royalty interests to Royalty Pharma for approximately $1.1 billion in upfront cash with over $1.5 billion in total potential value Launched tender offer for outstanding 3.25% Convertible Senior Notes DUBLIN, Aug. 4, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASD

DUBLIN, July 28, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ:TBPH) will report its second quarter 2022 financial results and provide a business update after market close on Thursday, August 4, 2022. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm ET (2:00 pm PT/10:00 pm IST) that day. Conference Call Information To participate in the live call by telephone, please dial (800) 225-9448 from the US or (203) 518-9708 for international callers, using the conference code TBPHQ222. Those interested in listening to the conference call liv

Over $1.5 Billion in Potential Total Value, Including Approximately $1.1 Billion in Upfront Cash, up to $250 Million in Sales-Based Milestone Payments and an Estimated NPV Approximately $200 Million of Rights to TRELEGY ELLIPTA Outer Year Royalties1Royalty Pharma to Invest up to $40 Million to Advance Development of Ampreloxetine in Multiple System Atrophy (MSA) in Exchange for Unsecured Low Single-Digit Royalties Theravance Biopharma to Hold a Conference Call Today at 5 pm ET / 2 pm PT / 10 pm ISTDUBLIN, July 13, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ:TBPH) today announced it has entered into a definitive agreement to sell all of it

DUBLIN, May 2, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ:TBPH) will report its first quarter 2022 financial results and provide a business update after market close on Thursday, May 5, 2022. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm ET (2:00 pm PT/10:00 pm IST) that day. Conference Call InformationTo participate in the live call by telephone, please dial (800) 225-9448 from the US or (203) 518-9783 for international callers, using the conference code TBPH0505. Those interested in listening to the conference call live via t

DUBLIN, Feb. 23, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ:TBPH) today reported financial results for the fourth quarter and full year ended December 31, 2021. "While COVID continues to impact communities around the country and health systems are strained, YUPELRI saw the highest quarter of net sales since its launch," said Rick E Winningham, Chief Executive Officer. "I am proud of our team and their ability to find a way to service the COPD community during this challenging time. YUPELRI once a day dosing is proving inc

DUBLIN, Feb. 9, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ:TBPH) will report its fourth quarter and full year 2021 financial results and provide a business update after market close on Wednesday, February 23, 2022. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm ET (2:00 pm PT/10:00 pm GMT) that day. Conference Call InformationTo participate in the live call by telephone, please dial (855) 296-9648 from the US or (920) 663-6266 for international callers, using the confirmation code 7456139. Those interested in listening to the co

DUBLIN, Nov. 3, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ:TBPH) today reported financial results for the third quarter of 2021. "This last month has been about executing on our strategy to create a new Theravance Biopharma, focused on leveraging expertise in developing and commercializing respiratory therapeutics. We are executing against the strategic plan we announced in mid-September to become cash-flow positive by the second-half of 2022," said Rick E Winningham, Chief Executive Officer. "We are on track to reduce he

DUBLIN, Oct. 20, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ:TBPH), will report its third quarter 2021 financial results and provide a business update after market close on Wednesday, November 3, 2021. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm ET (2:00 pm PT/9:00 pm IST) that day. Conference Call InformationTo participate in the live call by telephone, please dial (855) 296-9648 from the US or (920) 663-6266 for international callers, using the confirmation code 9772385. Those interested in listening to the conference call l

DUBLIN and SOUTH SAN FRANCISCO, Calif., Sept. 15, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ:TBPH) today announced strategic actions to focus on leveraging its expertise in developing and commercializing respiratory therapeutics in order to maximize shareholder value. These changes follow a comprehensive scenario planning exercise led by the Board and Management with the assistance of outside advisors. In order to implement this plan, Theravance Biopharma will immediately initiate a significant cost reduction program: Head

DUBLIN and SOUTH SAN FRANCISCO, Calif., Aug. 23, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ:TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development, and commercialization of organ-selective medicines, today announced top-line results from its Phase 2b dose-finding induction study of izencitinib, an orally administered, gut-selective pan-Janus kinase (JAK) inhibitor in development for the treatment of ulcerative colitis.  The study did not meet its primary endpoint of change in the tot

DUBLIN, Ireland, July 20, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ:TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, will report its second quarter 2021 financial results and provide a business update after market close on Tuesday, August 3, 2021. An accompanying conference call and simultaneous webcast will be hosted at 5:00 p.m. ET (2:00 p.m. PT/10:00 p.m. IST) that day. Conference Call Information To participate in the live call by telephone, please dial (855) 296